

Participation of SLOVENIAN CANCER REGISTRY

at

iPAAC Joint Action Work Package 7: Cancer Information and Registries

assoc. prof. Vesna ZADNIK, MD, PhD vzadnik@onko-i.si www.slora.si/en

OBVLADOVANJE RAKA V EU – KAKO NAPREJ Ljubljana, 31 May





WP 7 Cancer Information and Registries

Roberta De Angelis, MSc, Scientific coordinator iPAAC WP 7 Istituto Superiore di Sanità (ISS), Rome, IT




Co-funded by the Health Programme of the European Union



CANCER REGISTRIES: A KEY INFORMATION SYSTEM FOR CCC

- Un-biased, accurate, representative data. Indispensable for epidemiological research and evidence-based cancer control
- Integration with other health data to collect clinical information on the entire pathway of care is still a challenge
- Room to improve the potential of CR in most MS and to strengthen their support to address clinically relevant issues



PAAC

NNOVATIVE PARTNERSHIP FOR ACTION AGAINST CANCER



WP-7 OBJECTIVES



Actions to enhance population-based cancer information systems

to better support evidence-based comprehensive cancer care

1. To advance current registries datasets Task 1-5

Piloting the integration with *clinical and administrative electronic data in order* to derive key indicators on cancer care pathway and costs

2. To expand information available from current registries datasets Task 6

Promoting the use of more informative epidemiological indicators on cancer prevalence at European MS level



1. ADVANCING REGISTRIES DATASETS

iPAAC INNOVATIVE PARTNERSHIP FOR ACTION AGAINST CANCER

Task 1 Mapping key administrative and clinical data sources

to integrate registries data

Task2

Pilot study to integrate data on cancer pathways

Task3

Pilot study to integrate data on Cancer costs

Task 4

Pilot to integrate data on long term follow up of cancer survivors

Task 5

ICT model piloting a national cancer care information system by integrating multiple data sources



WP-7 PARTNERSHIP BY TASK



Task	Task 1: Mapping data source	Task 2: Pilot care pathways	Task 3: Pilot cancer costs	Task 4: Pilot long- term follow-up	Task 5: Pilot ICT model	Task 6: Indicators on cancer prevalence
Leader	INT, Italy	INT, Italy	ISS, Italy	INT, Italy	UZIS, Czech Rep	ISS, Italy
Partners	 ISS,UNI-FG, ISPRO, Italy UZIS,MUNI, Czech Rep IPHS, Serbia NIPH – NIH, Poland NIJZ (OIL), Slovenia NCPHA, Bulgaria MFH, Malta IMSP, Moldova RIVM, 	 ISS, UNI-FG, ISPRO, Italy NIJZ (OIL), Slovenia 7HRC, Greece RIVM, Netherlands ICO, Spain NIPH – NIH, Poland INSP, Romania 	 INT, ISPRO, Italy BMG, Germany HZJZ, Croatia NIPH – NIH, Poland RIVM, Netherlands WIV-ISP, Belgium DGS, Portugal 	 ISS, Italy NIJZ (OIL), Slovenia BMG, Germany CRN (OUS), Norway RIVM, Netherlands INSP IOCN), Romania DGS, Portugal ICO, Spain 	 ISS, MoH, Italy IPHS, Serbia IMSP IO, Moldova HZJZ, Croatia 	 INT, CRO, ISPRO, MoH, Italy WIV-ISP, Belgium NCPHA, Bulgaria HZJZ, Croatia RIVM, Netherlands CRN (OUS), Norway NIPH – NIH, Poland INSP, Romania ICO, Spain
Sub-	Netherlands	OECI			• ECPC	• ECPC
contracts	• AIRTUM	• AIRTUM	• AIRTUM	• AIRTUM	• AIRTUM	AIRTUM



Task 1 Mapping key administrative and clinical data sources to integrate registries data







Information gathering form for the Cancer Registries (CR) participating in the Project iPAAC WP7 <u>TASK 1: mapping key data sources to integrate registries data</u>

(After filling out, save and send via email to: support.cr@istitutotumori.mi.it)

1. CR FEATURES

- a) General Data
 - I. Name of the Cancer Registry

	Cancer	Cancer Registry of Republic of Slovenia				
П.	Country	Slovenia				
		Epidemiology and Cancer Registry, Institute of Oncology Ljubljana, Zaloska cesta 2, SI-1000 Ljubljana, Slovenia				
IV.	WEB Site	http://www.slora.si/en/ and https://www.onko-i.si/eng/crs/				
v		Vesna Zadnik, MD, PhD, professor of public health				



SLOVENIAN CANCER REGISTRY proposal for participation

iPAAC Joint Action Work Package 7: Cancer Information and Registries

assoc. prof. Vesna ZADNIK, MD, PhD vzadnik@onko-i.si www.slora.si/en

Rome, 12-13 March 2019



Slovenian Cancer Registry

General cancer registry Population-based Compulsory notification Follow-up through Central Population Registry

Slovenian Cancer Registry: data sources

Notifications from all hospitals NO Death Certificates, screening registries AUTOMATIC Hospital IS: Institute of Oncology Ljubljana IINKAGE National clinical melanoma registry AUTOMATIC



Task2

Pilot study to integrate data on cancer pathways

AIMS OF THE PILOT STUDY - TASK 7.2

This pilot study will evaluate the **feasibility of linking individual patient's data included in the participating population-based CRs, with administrative and health data,** in order to:

- 1) describe the complete pathway of cancer patients from diagnosis to rehabilitation or terminal care, including the use of health care resources at the end of life;
- 2) assess the adherence of the administered treatments to standard clinical guidelines.



EPIDEMIOLOGIIA IN REGISTER

Slovenian Cancer Registry Pilot 7.2

- Skin melanoma cohort Slovenian CR
 - Prevalence on date 31.12.2017
 - Diagnosed within last two years (from 1.1.2016 to 13.12.2017)
 - Follow up till 31.12.2018
- Clinical Melanoma Registry:
 - Details on melanoma treatment, all indicators on standard care (entire pathway; general and site specific)
 - Molecular status, mutation testing
 - Details on staging (eg. Breslow)
 - End of life QI:
 - · Chemotherapy use in the last 2 weeks of life
 - Death in acute care hospital



EPIDEMIOLOGIIA IN REGISTER RAKA

Slovenian Cancer Registry Pilot 7.2

- Causes of death Slovenian CR (already obtained from National Public Health Institute)
- Vital status Slovenian CR (already obtained from Central Population Register)
- EDI (SES) data available estimation on small geographical level
- Hospital admissions (DRG) unavailable

Task2 Pilot study to integrate data on cancer pathways



EPIDEMIOLOGIJA IN REGISTER RAKA EPIDEMIOLOGY AND CANCER REGISTRY

For each tumour under study

- Type of hospital (oncological, general hospital, oncological department within general hospital) where patients received the main treatments

- Indicators of quality of care at the end of life: in this phase high hospitalisation or anticancer drugs use are considered indicator of inappropriate care (*Barbera et al. Quality of end-of-life cancer care in Canada: a retrospective four-province study using administrative health care data. Curr Oncol.* 2015;22:341-55):

At least one among

- a new hospital admission in the last 30 days of life,
- intensive care unit (ICU) admission in the last 30 days of life,
- chemotherapy use in the last 2 weeks of life,
- death in an acute care hospital

Indicators of standard care for skin melanoma (*Dummer R et al. Cutaneous melanoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2015;26: v136-132.*)


At least one indicator among the following ones:

- Percentage of stage IV melanomas receiving mutation testing
- Percentage of melanomas with information on the maximum thickness in millimetres (Breslow)

 Percentage of melanoma patients with a tumour thickness of >1 mm receiving sentinel lymph node biopsy

Percentage of metastatic melanoma patients treated with immunotherapy







The **pilot 7.4** will focus on AYA (15-39 years at cancer diagnosis) cancer survivors (alive at least 5 years from the cancer diagnosis) with the following **objectives**:

- to define, in each country involved in this pilot, a cohort of AYA cancer survivors,
- to estimate the burden of late effects using data sources available and/or accessible by cancer registry,
- to assess the feasibility of comparing late effect indicators across the different countries involved in the pilot.



Slovenian Cancer Registry Pilot 7.4

- All AYA cancers Slovenian CR
 - Incidence cohort from 1980 to 2014
 - 5-years survivals
- Secondary primary cancers for AYA survival cohort - Slovenian CR
- Causes of death Slovenian CR (already obtained from National Public Health Institute)
- Vital status Slovenian CR (already obtained from Central Population Register)
- Primary treatment (not drugs)
- Late effects of cancer treatment for childhood cancer (0-14) – Late affect database
- Hospital admissions unavailable
- SES data unavailable



Task 4 Pilot to integrate data on long term follow up of cancer survivors



EPIDEMIOLOGIJA IN REGISTER RAKA EPIDEMIOLOGY AND CANCER REGISTRY

Late effects that will be studied include clinical and socio economic outcomes

- 1) <u>Clinical outcomes</u>
- Multiple subsequent malignant neoplasms (overall and by cancer specific groups)
- Hospitalizations (overall and by cause specific such as: Infectious and parasitic diseases, Endocrine nutritional and metabolic diseases, and immunity disorders, Diseases of the blood and blood-forming organs, Diseases of the nervous system and sense organs...)
- Mortality (all cause and by specific cause such as Diseases of the nervous system and sense organs, Diseases of the circulatory system, Malignant neoplasms....)
- Infertility and/or complications of pregnancy, childbirth, and the puerperium
- Congenital anomalies

2) Socio-economic outcomes

- Education level
- Marital status
- Household organization/social network (living independently; living alone, living together (partner in unmarried couple with and without children, partner in married couple with and without children); one-parent household and people living with relatives or others who are not partners).
- Utilisation of social/financial benefit (for unemployment, for disability)
- Occupation

In addition, we will check with CR the availability of sources with information about the treatment as a possible explicative variables of late effects.

Indicators



standardized mortality ratio (SMR)

standardized incidence ratio (SIR)

- standardized hospitalization ratio (SHR)
- odds ratio of attaining a low education level, of not getting married, not benefiting of a social network, of being financially dependent, of being unemployed.